Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages
01:33am, Friday, 03'rd Apr 2026
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) has received a consensus recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat reports. One equities research
Invivyd Announces Presentation at the World Vaccine Congress Washington
04:05pm, Monday, 30'th Mar 2026
NEW HAVEN, Conn., March 30, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Robert Allen, Ph.D., Chief Scientific Officer at Invivyd, presented as part of the Antibodies for
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching
11:22am, Friday, 20'th Mar 2026
Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, b
Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages
01:30am, Monday, 09'th Mar 2026
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) has received an average recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One investment
Invivyd Q4 Earnings Call Highlights
04:49am, Saturday, 07'th Mar 2026
Invivyd (NASDAQ: IVVD) executives used the company's fourth-quarter 2025 earnings call to outline progress in its COVID-19 monoclonal antibody pipeline, provide an update on commercialization of PEMGA
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
11:25am, Thursday, 05'th Mar 2026
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business hi
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
07:01am, Thursday, 05'th Mar 2026
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer.
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
04:10pm, Monday, 02'nd Mar 2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 02'nd Mar 2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an
NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of
NEW HAVEN, Conn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has received and is aligned with advice from the U.S. Food and Drug Administration (FDA) on the LIBE
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody
Invivyd (NASDAQ:IVVD) Shares Up 10.6% – What’s Next?
04:46am, Sunday, 11'th Jan 2026
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report)'s share price shot up 10.6% on Friday. The stock traded as high as $2.72 and last traded at $2.7750. 986,174 shares changed hands during mid-day trading,
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
07:01am, Thursday, 08'th Jan 2026
NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights.
